1. Home
  2. ETNB vs HE Comparison

ETNB vs HE Comparison

Compare ETNB & HE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ETNB
  • HE
  • Stock Information
  • Founded
  • ETNB 2018
  • HE 1891
  • Country
  • ETNB United States
  • HE United States
  • Employees
  • ETNB 93
  • HE N/A
  • Industry
  • ETNB Biotechnology: Pharmaceutical Preparations
  • HE Electric Utilities: Central
  • Sector
  • ETNB Health Care
  • HE Utilities
  • Exchange
  • ETNB Nasdaq
  • HE Nasdaq
  • Market Cap
  • ETNB 2.2B
  • HE 1.9B
  • IPO Year
  • ETNB 2019
  • HE N/A
  • Fundamental
  • Price
  • ETNB $14.83
  • HE $11.29
  • Analyst Decision
  • ETNB Buy
  • HE Hold
  • Analyst Count
  • ETNB 10
  • HE 4
  • Target Price
  • ETNB $22.31
  • HE $10.94
  • AVG Volume (30 Days)
  • ETNB 9.5M
  • HE 1.6M
  • Earning Date
  • ETNB 11-06-2025
  • HE 11-07-2025
  • Dividend Yield
  • ETNB N/A
  • HE N/A
  • EPS Growth
  • ETNB N/A
  • HE N/A
  • EPS
  • ETNB N/A
  • HE N/A
  • Revenue
  • ETNB N/A
  • HE $3,122,881,000.00
  • Revenue This Year
  • ETNB N/A
  • HE $12.58
  • Revenue Next Year
  • ETNB N/A
  • HE $2.10
  • P/E Ratio
  • ETNB N/A
  • HE N/A
  • Revenue Growth
  • ETNB N/A
  • HE 2.36
  • 52 Week Low
  • ETNB $4.16
  • HE $8.14
  • 52 Week High
  • ETNB $15.06
  • HE $13.41
  • Technical
  • Relative Strength Index (RSI)
  • ETNB 79.17
  • HE 43.81
  • Support Level
  • ETNB $14.67
  • HE $10.92
  • Resistance Level
  • ETNB $14.93
  • HE $11.26
  • Average True Range (ATR)
  • ETNB 0.09
  • HE 0.22
  • MACD
  • ETNB 0.06
  • HE -0.06
  • Stochastic Oscillator
  • ETNB 41.03
  • HE 28.06

About ETNB 89bio Inc.

89bio Inc is a United States-based clinical-stage biopharmaceutical company focused on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its product candidate, pegozafermin (previously BIO89-100), a specifically engineered glycoPEGylated analog of fibroblast growth factor 21 (FGF21), is currently being developed for the treatment of nonalcoholic steatohepatitis (NASH) and for the treatment of severe hypertriglyceridemia (SHTG).

About HE Hawaiian Electric Industries Inc.

Hawaiian Electric Industries is the parent company of three Hawaii-based regulated utilities and owns a 10% minority interest in Hawaii's American Savings Bank. The utilities provide electricity on the five islands of Oahu, Hawaii, Maui, Molokai, and Lanai.

Share on Social Networks: